From the map or links below, choose a site near you to learn more.

The Drug-Induced Liver Injury Network (DILIN) has been established to conduct research into the causes of drug-induced liver disease (DILI). DILIN is a nonprofit endeavor sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health.

Some of the most severe drug reactions affect the liver. In fact, DILI is the most common reason why drugs are not approved by the Food and Drug Administration in the first place or are removed from the market after they have been approved. DILIN hopes to be able to discover why some people have these unwanted liver reactions and others do not.

Two studies are being conducted by DILIN. In the Retrospective Study, we will establish a registry of people who experienced a liver injury due to taking certain prescribed medications since 1994. The four drugs are isoniazid (INH), phenytoin (Dilantin), clavulanic acid/amoxicillin (Augmentin), and valproic acid (Depakote). They were chosen because they have a characteristic, or "signature," clinical presentation, making them good candidates for scientific research. In the Prospective Study, patients who recently experienced an adverse liver reaction after taking any drug or herbal medicine will be studied. We will follow these patients over time to find out what happens to them as a result of their injury.

DILIN needs as many people as possible to participate in these two important studies. Ultimately, we hope to make it possible to design safer drugs in the future, which would benefit everyone.

To Top